ASP3652 + Gemfibrozil + Repaglinide

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Drug-Drug Interaction (DDI)

Conditions

Drug-Drug Interaction (DDI), Healthy Subjects

Trial Timeline

Apr 1, 2012 → Jun 1, 2012

About ASP3652 + Gemfibrozil + Repaglinide

ASP3652 + Gemfibrozil + Repaglinide is a phase 1 stage product being developed by Astellas Pharma for Drug-Drug Interaction (DDI). The current trial status is completed. This product is registered under clinical trial identifier NCT01797198. Target conditions include Drug-Drug Interaction (DDI), Healthy Subjects.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01797198Phase 1Completed

Competing Products

15 competing products in Drug-Drug Interaction (DDI)

See all competitors